News

PharmaSwiss, Israeli licensee of BioSante Pharmaceuticals, has submitted a new drug application (NDA) for Elestrin in Israel. The Elestrin filing is based on BioSante’ FDA approved NDA for

Laboratory Corporation of America and Monogram Biosciences have entered into an agreement and plan of merger. As per the agreement, LabCorp will acquire all of the outstanding shares

Cytopia has filed an Investigational New Drug Application (IND) with the FDA for orally active JAK2 inhibitor, CYT387. The company plans to start a phase I/II trial for

Takeda’ investigational compound, TAK-536 has entered into phase-III clinical trials in Japan. TAK-536 is a novel angiotensin receptor blocker (ARB) that is meant to lower blood pressure by

GlaxoSmithKline (GSK) and Chroma Therapeutics have signed a collaboration agreement to develop macrophage-targeted compounds, using Chroma’ proprietary esterase-sensitive motif (ESM) technology. Chroma would undertake four discovery and development

Baxter has signed a definitive agreement with Edwards Lifesciences to acquire certain assets related to Edwards’ hemofiltration product line, also known as Continuous Renal Replacement Therapy (CRRT). The

YM BioSciences’ licensee for nimotuzumab, Daiichi-Sankyo has initiated the enrollment of a phase II trial. It is to evaluate nimotuzumab, in combination with radiation therapy/cisplatin/vinorelbine, in first-line curative

Resolvyx has initiated the first human phase-I clinical trial, evaluating an oral resolvin therapeutic, RX-10001 in healthy volunteers. RX-10001 is a synthetic form of RvE1, a naturally occurring

Cerulean has signed a worldwide license agreement with Calando Pharma, a subsidiary of Arrowhead Research Corporation. Under the agreement, Cerulean has acquired worldwide rights to Calando’ proprietary cyclodextrin